4.2 Article

Serial measurements of C-reactive protein after acute myocardial infarction in predicting one-year outcome

期刊

INTERNATIONAL HEART JOURNAL
卷 47, 期 6, 页码 833-842

出版社

INT HEART JOURNAL ASSOC
DOI: 10.1536/ihj.47.833

关键词

systemic markers of inflammation; C-reactive protein; ST-elevation acute; myocardial infarction; risk markers; outcome

向作者/读者索取更多资源

Systemic markers of inflammation are considered reliable predictors of future coronary events in patients with acute myocardial infarction (AMI). The aim of this study was to evaluate the prognostic relevance of serial C-reactive protein (CRP) measurements in patients with ST-elevation AMI (STEMI) on one-year outcome. In 31 patients with STEMI, serial measurements of CRP were obtained, and for each patient, the following values were determined: (i) values at admission, up to 12 hours after symptom onset, (ii) maximal values obtained 24-72 hours after symptom onset (early acute values), and (iii) late acute values (96-120 hours after symptom onset). The combined endpoint was any new cardiovascular event, including death. Early and late acute CRP levels were the only parameters found to be significantly higher in patients with an adverse outcome than in patients with a good outcome. A significantly higher rate of endpoint events was found in patients with elevated early (Hazard ratio [HR] 5.54, 95%CI 2.05-25.40; P = 0.007) and late acute CRP (HR 9.01, 95% CI 1.66-19.56; P = 0.005). Multiple logistic regression analysis identified only early acute CRP as an independent predictor of an unfavorable outcome (Odds ratio 8.00, 95%CI 1.15-55.60; P 0.04), after adjustment for established risk factors. CRP level measured 24-72 hours after symptom onset is an independent predictor of one-year outcome in patients with STEML Values obtained later in the setting of STEMI do not add further prognostic information. CRP at admission is not related to long-term prognosis'.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据